Loading…
Lobbying Spend
—
Filings
88
Firms Hired
3
Active Period
2019–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Patent quality issues and preserving the Patent Trial and Appeal Board (PTAB). S. 1553, HR 3160, the PREVAIL Act; S. 1546, HR 3152, the Patent Eligibility Restoration Act of 2023
Client expense: — · Firm income: $40,000
Matched citations: HR 3152
Patent quality issues and preserving the Patent Trial and Appeal Board (PTAB). S. 1553, HR 3160, the PREVAIL Act; S. 1546, HR 3152, the Patent Eligibility Restoration Act of 2023
Client expense: — · Firm income: $40,000
Matched citations: HR 3160
Teaching Asian Pacific American History Act
2026 · third_quarter · Firm: TWINLOGIC STRATEGIES, LLP
Patent quality issues and preserving the Patent Trial and Appeal Board (PTAB). S. 1553, HR 3160, the PREVAIL Act; S. 1546, HR 3152, the Patent Eligibility Restoration Act of 2023
Client expense: — · Firm income: $40,000
Matched citations: S. 1546
Patent quality issues and preserving the Patent Trial and Appeal Board (PTAB). S. 1553, HR 3160, the PREVAIL Act; S. 1546, HR 3152, the Patent Eligibility Restoration Act of 2023
Client expense: — · Firm income: $40,000
Matched citations: S. 1553
Litigation Transparency Act of 2025
2026 · third_quarter · Firm: FRANKLIN SQUARE GROUP, LLC
Issues related to intellectual property legislation and regulation; H.R. 3152/S. 1546, Patent Eligibility Restoration Act of 2025; H.R. 3160/S. 1553, Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act); H.R. 1574/S. 708, RESTORE Patent Rights Act of 2025; USPTO Rulemaking related to Inter Partes Review; H.R. 9142, Prohibiting Adversarial Patents Act; H.R. 1109, Litigation Transparency Act of 2025; S. 3826, Litigation Funding Transparency Act of 2026; H.R. 2675, Protecting Our Courts from Foreign Manipulation Act; H.R. 7015, Protecting TPLF From Abuse Act
Client expense: — · Firm income: $70,000
Matched citations: H.R. 1109
RESTORE Patent Rights Act of 2025
2026 · third_quarter · Firm: FRANKLIN SQUARE GROUP, LLC
Issues related to intellectual property legislation and regulation; H.R. 3152/S. 1546, Patent Eligibility Restoration Act of 2025; H.R. 3160/S. 1553, Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act); H.R. 1574/S. 708, RESTORE Patent Rights Act of 2025; USPTO Rulemaking related to Inter Partes Review; H.R. 9142, Prohibiting Adversarial Patents Act; H.R. 1109, Litigation Transparency Act of 2025; S. 3826, Litigation Funding Transparency Act of 2026; H.R. 2675, Protecting Our Courts from Foreign Manipulation Act; H.R. 7015, Protecting TPLF From Abuse Act
Client expense: — · Firm income: $70,000
Matched citations: H.R. 1574
Protecting Our Courts from Foreign Manipulation Act
2026 · third_quarter · Firm: FRANKLIN SQUARE GROUP, LLC
Issues related to intellectual property legislation and regulation; H.R. 3152/S. 1546, Patent Eligibility Restoration Act of 2025; H.R. 3160/S. 1553, Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act); H.R. 1574/S. 708, RESTORE Patent Rights Act of 2025; USPTO Rulemaking related to Inter Partes Review; H.R. 9142, Prohibiting Adversarial Patents Act; H.R. 1109, Litigation Transparency Act of 2025; S. 3826, Litigation Funding Transparency Act of 2026; H.R. 2675, Protecting Our Courts from Foreign Manipulation Act; H.R. 7015, Protecting TPLF From Abuse Act
Client expense: — · Firm income: $70,000
Matched citations: H.R. 2675
Patent Eligibility Restoration Act of 2025
2026 · third_quarter · Firm: FRANKLIN SQUARE GROUP, LLC
Issues related to intellectual property legislation and regulation; H.R. 3152/S. 1546, Patent Eligibility Restoration Act of 2025; H.R. 3160/S. 1553, Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act); H.R. 1574/S. 708, RESTORE Patent Rights Act of 2025; USPTO Rulemaking related to Inter Partes Review; H.R. 9142, Prohibiting Adversarial Patents Act; H.R. 1109, Litigation Transparency Act of 2025; S. 3826, Litigation Funding Transparency Act of 2026; H.R. 2675, Protecting Our Courts from Foreign Manipulation Act; H.R. 7015, Protecting TPLF From Abuse Act
Client expense: — · Firm income: $70,000
Matched citations: H.R. 3152
Issues related to intellectual property legislation and regulation; H.R. 3152/S. 1546, Patent Eligibility Restoration Act of 2025; H.R. 3160/S. 1553, Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act); H.R. 1574/S. 708, RESTORE Patent Rights Act of 2025; USPTO Rulemaking related to Inter Partes Review; H.R. 9142, Prohibiting Adversarial Patents Act; H.R. 1109, Litigation Transparency Act of 2025; S. 3826, Litigation Funding Transparency Act of 2026; H.R. 2675, Protecting Our Courts from Foreign Manipulation Act; H.R. 7015, Protecting TPLF From Abuse Act
Client expense: — · Firm income: $70,000
Matched citations: H.R. 3160
Protecting TPLF From Abuse Act
2026 · third_quarter · Firm: FRANKLIN SQUARE GROUP, LLC
Issues related to intellectual property legislation and regulation; H.R. 3152/S. 1546, Patent Eligibility Restoration Act of 2025; H.R. 3160/S. 1553, Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act); H.R. 1574/S. 708, RESTORE Patent Rights Act of 2025; USPTO Rulemaking related to Inter Partes Review; H.R. 9142, Prohibiting Adversarial Patents Act; H.R. 1109, Litigation Transparency Act of 2025; S. 3826, Litigation Funding Transparency Act of 2026; H.R. 2675, Protecting Our Courts from Foreign Manipulation Act; H.R. 7015, Protecting TPLF From Abuse Act
Client expense: — · Firm income: $70,000
Matched citations: H.R. 7015
Prohibiting Adversarial Patents Act of 2026
2026 · third_quarter · Firm: FRANKLIN SQUARE GROUP, LLC
Issues related to intellectual property legislation and regulation; H.R. 3152/S. 1546, Patent Eligibility Restoration Act of 2025; H.R. 3160/S. 1553, Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act); H.R. 1574/S. 708, RESTORE Patent Rights Act of 2025; USPTO Rulemaking related to Inter Partes Review; H.R. 9142, Prohibiting Adversarial Patents Act; H.R. 1109, Litigation Transparency Act of 2025; S. 3826, Litigation Funding Transparency Act of 2026; H.R. 2675, Protecting Our Courts from Foreign Manipulation Act; H.R. 7015, Protecting TPLF From Abuse Act
Client expense: — · Firm income: $70,000
Matched citations: H.R. 9142
Patent Eligibility Restoration Act of 2025
2026 · third_quarter · Firm: FRANKLIN SQUARE GROUP, LLC
Issues related to intellectual property legislation and regulation; H.R. 3152/S. 1546, Patent Eligibility Restoration Act of 2025; H.R. 3160/S. 1553, Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act); H.R. 1574/S. 708, RESTORE Patent Rights Act of 2025; USPTO Rulemaking related to Inter Partes Review; H.R. 9142, Prohibiting Adversarial Patents Act; H.R. 1109, Litigation Transparency Act of 2025; S. 3826, Litigation Funding Transparency Act of 2026; H.R. 2675, Protecting Our Courts from Foreign Manipulation Act; H.R. 7015, Protecting TPLF From Abuse Act
Client expense: — · Firm income: $70,000
Matched citations: S. 1546
Issues related to intellectual property legislation and regulation; H.R. 3152/S. 1546, Patent Eligibility Restoration Act of 2025; H.R. 3160/S. 1553, Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act); H.R. 1574/S. 708, RESTORE Patent Rights Act of 2025; USPTO Rulemaking related to Inter Partes Review; H.R. 9142, Prohibiting Adversarial Patents Act; H.R. 1109, Litigation Transparency Act of 2025; S. 3826, Litigation Funding Transparency Act of 2026; H.R. 2675, Protecting Our Courts from Foreign Manipulation Act; H.R. 7015, Protecting TPLF From Abuse Act
Client expense: — · Firm income: $70,000
Matched citations: S. 1553
Litigation Funding Transparency Act of 2026
2026 · third_quarter · Firm: FRANKLIN SQUARE GROUP, LLC
Issues related to intellectual property legislation and regulation; H.R. 3152/S. 1546, Patent Eligibility Restoration Act of 2025; H.R. 3160/S. 1553, Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act); H.R. 1574/S. 708, RESTORE Patent Rights Act of 2025; USPTO Rulemaking related to Inter Partes Review; H.R. 9142, Prohibiting Adversarial Patents Act; H.R. 1109, Litigation Transparency Act of 2025; S. 3826, Litigation Funding Transparency Act of 2026; H.R. 2675, Protecting Our Courts from Foreign Manipulation Act; H.R. 7015, Protecting TPLF From Abuse Act
Client expense: — · Firm income: $70,000
Matched citations: S. 3826
RESTORE Patent Rights Act of 2025
2026 · third_quarter · Firm: FRANKLIN SQUARE GROUP, LLC
Issues related to intellectual property legislation and regulation; H.R. 3152/S. 1546, Patent Eligibility Restoration Act of 2025; H.R. 3160/S. 1553, Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act); H.R. 1574/S. 708, RESTORE Patent Rights Act of 2025; USPTO Rulemaking related to Inter Partes Review; H.R. 9142, Prohibiting Adversarial Patents Act; H.R. 1109, Litigation Transparency Act of 2025; S. 3826, Litigation Funding Transparency Act of 2026; H.R. 2675, Protecting Our Courts from Foreign Manipulation Act; H.R. 7015, Protecting TPLF From Abuse Act
Client expense: — · Firm income: $70,000
Matched citations: S. 708
I've lobbied in opposition to creating a presumption of irreparable harm in patent litigation under the RESTORE Patent Rights Act of 2025 (S.708, H.R.1574), against weakening the Patent Trial and Appeal Board through administrative or legislative action (e.g., the PREVAIL Act, H.R.4370, S.2220, S.1553), and against the expansion of patent eligibility in the Patent Eligibility Restoration Act (S.2140, H.R.9474, S.1546). I have also supported disclosure of third-party litigation funding (e.g., H.R.1109 and S.3826). I have also supported limitations on foreign entities that represent a national security risk obtaining and enforcing U.S. patents (e.g., H.R.9142, the Prohibiting Adversarial Patents Act).
Client expense: — · Firm income: $110,000
Matched citations: H.R.4370
Patent Eligibility Restoration Act of 2024
2026 · third_quarter · Firm: DAVID W JONES
I've lobbied in opposition to creating a presumption of irreparable harm in patent litigation under the RESTORE Patent Rights Act of 2025 (S.708, H.R.1574), against weakening the Patent Trial and Appeal Board through administrative or legislative action (e.g., the PREVAIL Act, H.R.4370, S.2220, S.1553), and against the expansion of patent eligibility in the Patent Eligibility Restoration Act (S.2140, H.R.9474, S.1546). I have also supported disclosure of third-party litigation funding (e.g., H.R.1109 and S.3826). I have also supported limitations on foreign entities that represent a national security risk obtaining and enforcing U.S. patents (e.g., H.R.9142, the Prohibiting Adversarial Patents Act).
Client expense: — · Firm income: $110,000
Matched citations: H.R.9474
Litigation Transparency Act of 2025
2026 · third_quarter · Firm: DAVID W JONES
I've lobbied in opposition to creating a presumption of irreparable harm in patent litigation under the RESTORE Patent Rights Act of 2025 (S.708, H.R.1574), against weakening the Patent Trial and Appeal Board through administrative or legislative action (e.g., the PREVAIL Act, H.R.4370, S.2220, S.1553), and against the expansion of patent eligibility in the Patent Eligibility Restoration Act (S.2140, H.R.9474, S.1546). I have also supported disclosure of third-party litigation funding (e.g., H.R.1109 and S.3826). I have also supported limitations on foreign entities that represent a national security risk obtaining and enforcing U.S. patents (e.g., H.R.9142, the Prohibiting Adversarial Patents Act).
Client expense: — · Firm income: $110,000
Matched citations: H.R.1109
I've lobbied in opposition to creating a presumption of irreparable harm in patent litigation under the RESTORE Patent Rights Act of 2025 (S.708, H.R.1574), against weakening the Patent Trial and Appeal Board through administrative or legislative action (e.g., the PREVAIL Act, H.R.4370, S.2220, S.1553), and against the expansion of patent eligibility in the Patent Eligibility Restoration Act (S.2140, H.R.9474, S.1546). I have also supported disclosure of third-party litigation funding (e.g., H.R.1109 and S.3826). I have also supported limitations on foreign entities that represent a national security risk obtaining and enforcing U.S. patents (e.g., H.R.9142, the Prohibiting Adversarial Patents Act).
Client expense: — · Firm income: $110,000
Matched citations: H.R.1574
Prohibiting Adversarial Patents Act of 2026
2026 · third_quarter · Firm: DAVID W JONES
I've lobbied in opposition to creating a presumption of irreparable harm in patent litigation under the RESTORE Patent Rights Act of 2025 (S.708, H.R.1574), against weakening the Patent Trial and Appeal Board through administrative or legislative action (e.g., the PREVAIL Act, H.R.4370, S.2220, S.1553), and against the expansion of patent eligibility in the Patent Eligibility Restoration Act (S.2140, H.R.9474, S.1546). I have also supported disclosure of third-party litigation funding (e.g., H.R.1109 and S.3826). I have also supported limitations on foreign entities that represent a national security risk obtaining and enforcing U.S. patents (e.g., H.R.9142, the Prohibiting Adversarial Patents Act).
Client expense: — · Firm income: $110,000
Matched citations: H.R.9142
Patent Eligibility Restoration Act of 2023
2026 · third_quarter · Firm: DAVID W JONES
I've lobbied in opposition to creating a presumption of irreparable harm in patent litigation under the RESTORE Patent Rights Act of 2025 (S.708, H.R.1574), against weakening the Patent Trial and Appeal Board through administrative or legislative action (e.g., the PREVAIL Act, H.R.4370, S.2220, S.1553), and against the expansion of patent eligibility in the Patent Eligibility Restoration Act (S.2140, H.R.9474, S.1546). I have also supported disclosure of third-party litigation funding (e.g., H.R.1109 and S.3826). I have also supported limitations on foreign entities that represent a national security risk obtaining and enforcing U.S. patents (e.g., H.R.9142, the Prohibiting Adversarial Patents Act).
Client expense: — · Firm income: $110,000
Matched citations: S.2140
I've lobbied in opposition to creating a presumption of irreparable harm in patent litigation under the RESTORE Patent Rights Act of 2025 (S.708, H.R.1574), against weakening the Patent Trial and Appeal Board through administrative or legislative action (e.g., the PREVAIL Act, H.R.4370, S.2220, S.1553), and against the expansion of patent eligibility in the Patent Eligibility Restoration Act (S.2140, H.R.9474, S.1546). I have also supported disclosure of third-party litigation funding (e.g., H.R.1109 and S.3826). I have also supported limitations on foreign entities that represent a national security risk obtaining and enforcing U.S. patents (e.g., H.R.9142, the Prohibiting Adversarial Patents Act).
Client expense: — · Firm income: $110,000
Matched citations: S.2220
Patent Eligibility Restoration Act of 2025
2026 · third_quarter · Firm: DAVID W JONES
I've lobbied in opposition to creating a presumption of irreparable harm in patent litigation under the RESTORE Patent Rights Act of 2025 (S.708, H.R.1574), against weakening the Patent Trial and Appeal Board through administrative or legislative action (e.g., the PREVAIL Act, H.R.4370, S.2220, S.1553), and against the expansion of patent eligibility in the Patent Eligibility Restoration Act (S.2140, H.R.9474, S.1546). I have also supported disclosure of third-party litigation funding (e.g., H.R.1109 and S.3826). I have also supported limitations on foreign entities that represent a national security risk obtaining and enforcing U.S. patents (e.g., H.R.9142, the Prohibiting Adversarial Patents Act).
Client expense: — · Firm income: $110,000
Matched citations: S.1546
I've lobbied in opposition to creating a presumption of irreparable harm in patent litigation under the RESTORE Patent Rights Act of 2025 (S.708, H.R.1574), against weakening the Patent Trial and Appeal Board through administrative or legislative action (e.g., the PREVAIL Act, H.R.4370, S.2220, S.1553), and against the expansion of patent eligibility in the Patent Eligibility Restoration Act (S.2140, H.R.9474, S.1546). I have also supported disclosure of third-party litigation funding (e.g., H.R.1109 and S.3826). I have also supported limitations on foreign entities that represent a national security risk obtaining and enforcing U.S. patents (e.g., H.R.9142, the Prohibiting Adversarial Patents Act).
Client expense: — · Firm income: $110,000
Matched citations: S.1553
Litigation Funding Transparency Act of 2026
2026 · third_quarter · Firm: DAVID W JONES
I've lobbied in opposition to creating a presumption of irreparable harm in patent litigation under the RESTORE Patent Rights Act of 2025 (S.708, H.R.1574), against weakening the Patent Trial and Appeal Board through administrative or legislative action (e.g., the PREVAIL Act, H.R.4370, S.2220, S.1553), and against the expansion of patent eligibility in the Patent Eligibility Restoration Act (S.2140, H.R.9474, S.1546). I have also supported disclosure of third-party litigation funding (e.g., H.R.1109 and S.3826). I have also supported limitations on foreign entities that represent a national security risk obtaining and enforcing U.S. patents (e.g., H.R.9142, the Prohibiting Adversarial Patents Act).
Client expense: — · Firm income: $110,000
Matched citations: S.3826
Source: Senate LDA